anti parp1 rabbit polyclonal antibodies  (Proteintech)

Journal: NAR Cancer

Article Title: PARP inhibitor response is enhanced in prostate cancer when XRCC1 expression is reduced

doi: 10.1093/narcan/zcaf015

Figure Lengend Snippet: Antibodies used for immunoblotting experiments

Article Snippet: Cleaved PARP1-D214 (#5625) , 1:500 , Cell Signaling Technology.

Techniques: Western Blot

Journal: NAR Cancer

Article Title: PARP inhibitor response is enhanced in prostate cancer when XRCC1 expression is reduced

doi: 10.1093/narcan/zcaf015

Figure Lengend Snippet: XRCC1 knockout increased PARPi-induced chromatin-associated PARP1 in PCa cells. ( A and B ) Immunoblots (left) and quantification (right) show the expression of PARP1 in soluble and chromatin fractions of C4-2B (A) and 22RV1 (B) vector control cells, XRCC1- KO C-1, and XRCC1- KO C-1 + XRCC1 following 24 h treatment with rucaparib only. α-Tubulin and H3 were used as a loading control for soluble and chromatin fractions, respectively. The level of statistical significance among the groups was computed using two-way ANOVA with Tukey’s multiple comparisons test. The level of statistical significance is indicated as follows: ** P < 0.01 and *** P < 0.001.

Article Snippet: Cleaved PARP1-D214 (#5625) , 1:500 , Cell Signaling Technology.

Techniques: Knock-Out, Western Blot, Expressing, Plasmid Preparation, Control

Journal: NAR Cancer

Article Title: PARP inhibitor response is enhanced in prostate cancer when XRCC1 expression is reduced

doi: 10.1093/narcan/zcaf015

Figure Lengend Snippet: XRCC1 depletion enhanced PARPi-induced apoptosis. ( A and B ) Representative apoptosis profiles of C4-2B (A) and 22RV1 (B) vector control cells and XRCC1- KO C-1 following 48 h treatment with 0.5 μM rucaparib using annexin V-PI dual staining-based flow cytometry. ( C and D ) The percent apoptotic population is indicated. ( E and F ) Immunoblots (left) and quantification (right) show the expression of cleaved and total PARP-1 in C4-2B (E) and 22RV1 (F) vector control cells, XRCC1- KO C-1, and XRCC1- KO C-1 + XRCC1 after 48 h treatment with 0.5 μM rucaparib. Actin was used as a loading control. The level of statistical significance among the groups was computed using two-way ANOVA with Tukey’s multiple comparisons test. The level of statistical significance is indicated as follows: * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001.

Article Snippet: Cleaved PARP1-D214 (#5625) , 1:500 , Cell Signaling Technology.

Techniques: Plasmid Preparation, Control, Staining, Flow Cytometry, Western Blot, Expressing